No More Mr. NICE Guy: Pfizer/Eisai Seek Court Review Of Cost-Effectiveness Appraisal For Alzheimer’s Drugs

Judicial review of U.K. appraisal limiting acetylcholinesterase inhibitors to moderately severe Alzheimer’s would mark the first time NICE has been challenged at that level, firms say.